Clinical Trials Logo

End Stage Renal Disease clinical trials

View clinical trials related to End Stage Renal Disease.

Filter by:

NCT ID: NCT04634916 Recruiting - Clinical trials for End-stage Renal Disease

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

CONNECT-AV
Start date: March 26, 2021
Phase: N/A
Study type: Interventional

A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.

NCT ID: NCT04623281 Completed - Clinical trials for End Stage Renal Disease

Haemodialysis Outcomes & Patient Empowerment Study 02

HOPE-02
Start date: January 21, 2021
Phase:
Study type: Observational

Pilot-scale, single-arm,observational study to assess the utility and acceptability of a wearable hydration monitor in haemodialysis patients compared with bioimpedance and haemodialysis machine data.

NCT ID: NCT04622215 Completed - Clinical trials for End Stage Renal Disease

Diuresis, Functional Bladder Capacity and LUTS in CKD and ESRD Patients.

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the prevalence of LUTS in patients with moderate to severe (Stage IIIb), severe (Stage IV) CKD and ESRD : Stage V CKD) without renal transplantation (both pre-dialysis and dialysis patients). The study will also investigate the correlation between the diuresis, functional bladder capacity and LUTS in this population. By means of the obtained results, the investigators hope to be able to predict at which values of diuresis and functional bladder capacity these patients will start to develop LUTS. The investigators will also evaluate the impact of LUTS on the quality of life of these patients.

NCT ID: NCT04614142 Withdrawn - Clinical trials for End Stage Renal Disease

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Start date: November 13, 2020
Phase: Phase 4
Study type: Interventional

This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

NCT ID: NCT04580420 Recruiting - Clinical trials for End Stage Renal Disease

Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD

PHYOX7
Start date: April 15, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate DCR-PHXC in participants with PH1 or PH2 and severe renal impairment, with or without dialysis.

NCT ID: NCT04575896 Completed - Hepatitis C Clinical Trials

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Start date: November 20, 2020
Phase: Phase 4
Study type: Interventional

In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant procedure and continued for 2 weeks post-renal transplant.

NCT ID: NCT04575077 Recruiting - Clinical trials for End-stage Renal Disease

The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation

Start date: September 16, 2020
Phase:
Study type: Observational

High hepcidin concentrations indicate that iron is blocked from secretion from the reservoir. Hepcidin may be useful in prediction functional iron utilization in renal failure patients. Hepcidin is also associated with chronic renal failure and residual renal function in dialysis patients. Recent studies have shown that hepcidin is a potential marker of impaired renal function in a rat model of chronic nephropathy. The purpose of this study was to investigate the relationship between preoperative hepcidin levels and the incidence of success rate of kidney transplantation in patients with end-stage renal failure undergoing kidney transplantation surgery. The study is a prospective single-group observational study that analyzes hepcidin as a biomarker.

NCT ID: NCT04571619 Completed - Chronic Pain Clinical Trials

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

HOPE
Start date: January 3, 2021
Phase: Phase 2
Study type: Interventional

HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid use, and that buprenorphine will be acceptable and tolerable as an approach to managing physical dependence on opioids in this patient population.

NCT ID: NCT04542304 Recruiting - Clinical trials for Chronic Kidney Disease

Efficacy of Diuretics in Kidney Disease

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This study will determine the efficacy of diuretics in patients with chronic kidney disease.

NCT ID: NCT04530175 Completed - Clinical trials for End Stage Renal Disease

Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

MARC
Start date: February 2, 2021
Phase:
Study type: Observational

The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium